GenBank Accession No. AC069200, May 24, 2000. |
Sulston et al., “Toward a complete human genome sequence,” Genome Research 8(11):1097-1108, 1998. |
GenBank Accession No. AF269087, Mar. 28, 2001. |
GenBank Accession No. AAK27325, Mar. 28, 2001. |
Chang and Shu, “Current status of adoptive immunotherapy of cancer,” Critical Reviews in Oncology/Hematology 22(3):213-228, Apr. 1996. |
Cheever and Chen, “Therapy with cultured T cells: principles revisited,” Immunological Reviews, 157: 177-194, 1997. |
Cheever et al., “Potential uses of interleukin 2 in cancer therapy,” Immunobiol, 172:365-382, 1986. |
Cole et al., “Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-melanoma antigent,” Cancer Research, 55:748-752, Feb. 15, 1995. |
Durrant L., “Cancer vaccines,” Anti-Cancer Drugs, 8:727-733, 1997. |
Eshhar Z., “Tumor-specific T-bodies: toward clinical application,” Cancer Immunol Immunother, 45:131-136, 1997. |
Hwu et al., “In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes,” Cancer Research, 55:3369-3373, Aug. 1, 1995. |
Porter-Jordan and Lippman, “Overview of the biologic markers of breast cancer,” Breast Cancer 8:(1):73-100, Feb. 1994. |
Wei et al., “Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA,” Int. J. Cancer, 81:748-754, 1999. |
GenBank Accession No. AA864891, Feb. 20, 1998. |
GenBank Accession No. AA398925, Apr. 25, 1997. |